Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) Short Interest Update

Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) was the target of a large decline in short interest in June. As of June 30th, there was short interest totaling 143,052 shares, a decline of 84.8% from the June 15th total of 942,551 shares. Based on an average trading volume of 1,785,958 shares, the short-interest ratio is currently 0.1 days. Approximately 12.1% of the company’s stock are sold short.

Institutional Investors Weigh In On Regentis Biomaterials

An institutional investor recently bought a new stake in Regentis Biomaterials stock. AIGH Capital Management LLC purchased a new stake in shares of Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 300,000 shares of the company’s stock, valued at approximately $916,000. AIGH Capital Management LLC owned about 5.79% of Regentis Biomaterials at the end of the most recent reporting period.

Regentis Biomaterials Trading Down 8.4%

Shares of NYSEAMERICAN:RGNT traded down $0.32 during midday trading on Monday, hitting $3.47. 71,522 shares of the stock were exchanged, compared to its average volume of 10,284,606. Regentis Biomaterials has a 52-week low of $1.23 and a 52-week high of $15.50. The stock’s fifty day moving average is $2.98.

Regentis Biomaterials Company Profile

Regentis Biomaterials Ltd. is a regenerative medicine company dedicated to developing tissue repair solutions which seek to restore the health. Regentis Biomaterials Ltd. is based in Herzliya, Israel.